No Data
No Data
We Think That There Are Issues Underlying Pacira BioSciences' (NASDAQ:PCRX) Earnings
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) stock was strong after they recently reported robust earnings. However, we think that shareholders may be missing some concerning details in the numbers. N
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes Due 2029
PDF Version TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior no
Pacira Biosciences Announces Proposed Offering of $250M Aggregate Principal Amount of Convertible Senior Notes
Pacira BioSciences Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Pacira BioSciences Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : Pacira BioSciences (PCRX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $57.00.
HC Wainwright & Co. : Pacira BioSciences (PCRX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $57.00.
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
HC Wainwright & Co. analyst Oren Livnat reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $57 price target.